Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.verified

ALDX

Price:

$4.79

Market Cap:

$285.24M

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for ...[Read more]

Industry

Biotechnology

IPO Date

2014-05-02

Stock Exchange

NASDAQ

Ticker

ALDX

The PE Ratio as of December 2024 (TTM) for Aldeyra Therapeutics, Inc. (ALDX) is -6.39

According to Aldeyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.39. This represents a change of 1.79% compared to the average of -6.28 of the last 4 quarters.

Aldeyra Therapeutics, Inc. (ALDX) Historical PE Ratio (quarterly & annually)

How has ALDX PE Ratio performed in the past?

The mean historical PE Ratio of Aldeyra Therapeutics, Inc. over the last ten years is -4.75. The current -6.39 PE Ratio has changed 13.37% with respect to the historical average. Over the past ten years (40 quarters), ALDX's PE Ratio was at its highest in in the March 2020 quarter at -1.83. The PE Ratio was at its lowest in in the June 2023 quarter at -13.72.

Quarterly (TTM)
Annual

Average

-4.75

Median

-4.84

Minimum

-6.62

Maximum

-2.59

Aldeyra Therapeutics, Inc. (ALDX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Aldeyra Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 139.59%

Maximum Annual PE Ratio = -2.59

Minimum Annual Increase = -3044.74%

Minimum Annual PE Ratio = -6.62

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.51-16.80%
2022-6.6281.57%
2021-3.65-41.20%
2020-6.20139.59%
2019-2.59-44.04%
2018-4.63-4.51%
2017-4.8549.21%
2016-3.25-32.92%
2015-4.84-8.89%
2014-5.31-3044.74%

Aldeyra Therapeutics, Inc. (ALDX) Average PE Ratio

How has ALDX PE Ratio performed in the past?

The current PE Ratio of Aldeyra Therapeutics, Inc. (ALDX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-5.26

5-year avg

-4.92

10-year avg

-4.75

Aldeyra Therapeutics, Inc. (ALDX) PE Ratio vs. Peers

How is ALDX’s PE Ratio compared to its peers?

Aldeyra Therapeutics, Inc.’s PE Ratio is greater than Tarsus Pharmaceuticals, Inc. (-15.51), less than LianBio (-0.75), less than Travere Therapeutics, Inc. (-3.76), greater than Eton Pharmaceuticals, Inc. (-58.93), less than Viridian Therapeutics, Inc. (-4.96), less than Terns Pharmaceuticals, Inc. (-5.08), greater than Structure Therapeutics Inc. (-12.71), greater than Blueprint Medicines Corporation (-44.46), less than 89bio, Inc. (-2.95), greater than X4 Pharmaceuticals, Inc. (-7.16), less than Inozyme Pharma, Inc. (-1.91), greater than Day One Biopharmaceuticals, Inc. (-14.45), less than HOOKIPA Pharma Inc. (-0.53), less than Phathom Pharmaceuticals, Inc. (-1.39), less than Lyra Therapeutics, Inc. (-0.11), less than Cullinan Oncology, Inc. (-4.96), less than BioLineRx Ltd. (-1.05), greater than Ardelyx, Inc. (-15.26), less than Lexicon Pharmaceuticals, Inc. (-1.25), less than Seres Therapeutics, Inc. (-5.88), less than ImmunityBio, Inc. (-3.11),

Build a custom stock screener for Aldeyra Therapeutics, Inc. (ALDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aldeyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aldeyra Therapeutics, Inc. (ALDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aldeyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Aldeyra Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Aldeyra Therapeutics, Inc. (ALDX)?

What is the highest PE Ratio for Aldeyra Therapeutics, Inc. (ALDX)?

What is the 3-year average PE Ratio for Aldeyra Therapeutics, Inc. (ALDX)?

What is the 5-year average PE Ratio for Aldeyra Therapeutics, Inc. (ALDX)?

How does the current PE Ratio for Aldeyra Therapeutics, Inc. (ALDX) compare to its historical average?